Ana Luísa João
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ana Luísa João has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
André Lencastre
Dermatology Department, Hospital de Cascais Dr Jose de Almeida, Alcabideche, Portugal
3 shared publications- André Lencastre
Dermatology Department, Hospital da Luz, Lisbon, Portugal
3 shared publications Cândida Fernandes
Dermatology and Venereology Department Centro Hospitalar Universitário de Lisboa Central Lisbon Portugal
3 shared publicationsNélia Cunha
Dermatology Department, Centro Hospitalar Universitário de Lisboa Central, Lisbon, Portugal
3 shared publicationsTomás Pessoa e Costa
Dermatology Department, Centro Hospitalar de Lisboa Central, Lisbon, Portugal
3 shared publicationsA.I. Cordeiro
Pediatrics Department, Centro Hospitalar Universitário de Lisboa Central, Lisbon, Portugal
2 shared publications
Latest Publications
- Open Access
- 15 December 2025
- Published by Instituto Mexicano del Seguro Social in Portuguese Journal of Dermatology and Venereology
- Vol. 83 (4)
Glucagon-like peptide-1 receptor agonists in dermatology: more than meets the eye
- 15 December 2025
- Published by Instituto Mexicano del Seguro Social in Portuguese Journal of Dermatology and Venereology
- Vol. 83 (4)
Open AccessGlucagon-like peptide-1 receptor agonists in dermatology: more than meets the eye
- 29 May 2024
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 39 (1) , e98-e99
Beyond genital screening: The role of extragenital testing for Chlamydia trachomatis in women
- 29 May 2024
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 39 (1) , e98-e99
Beyond genital screening: The role of extragenital testing for Chlamydia trachomatis in women
- 22 December 2023
- Published by BMJ in Sexually Transmitted Infections
- Vol. 100 (2) , 120
Mpox after vaccination: a case series
- 22 December 2023
- Published by BMJ in Sexually Transmitted Infections
- Vol. 100 (2) , 120
Mpox after vaccination: a case series
- Open Access
- 23 September 2023
- Published by Elsevier in Actas Dermo-Sifiliograficas
- Vol. 114 (10) , T921-T922
[Artículo traducido] Síndrome de Van der Woude y alopecia areata: más que una asociación fortuita?
- 23 September 2023
- Published by Elsevier in Actas Dermo-Sifiliograficas
- Vol. 114 (10) , T921-T922
Open Access[Artículo traducido] Síndrome de Van der Woude y alopecia areata: más que una asociación fortuita?
- 1 April 2023
- Published by JLE in European Journal Of Dermatology
- Vol. 33 (2) , 194-195
sQuiz your knowledge! A blue-greyish asymptomatic papule on the earlobe
- 1 April 2023
- Published by JLE in European Journal Of Dermatology
- Vol. 33 (2) , 194-195
sQuiz your knowledge! A blue-greyish asymptomatic papule on the earlobe
- Open Access
- 3 February 2023
- Published by Elsevier in Actas Dermo-Sifiliograficas
- Vol. 114 (10) , 921-922
Van der Woude Syndrome and Alopecia Areata: More Than a Fortuitous Association?
- 3 February 2023
- Published by Elsevier in Actas Dermo-Sifiliograficas
- Vol. 114 (10) , 921-922
Open AccessVan der Woude Syndrome and Alopecia Areata: More Than a Fortuitous Association?
- Open Access
- 13 October 2022
- Published by S. Karger AG in Case Reports in Dermatology
- Vol. 14 (3) , 302-306
Tocilizumab-Induced Erythema Annulare Centrifugum
We report the case of a 42-year-old woman with rheumatoid arthritis undergoing treatment with subcutaneous tocilizumab for the past 6 months. Three days after the administration, an asymptomatic inflammatory annular plaque of 4 cm with discrete whitish scales at the inner border margin developed at the injection site in the left iliac fossa. A smaller plaque in the left groin appeared soon after. The mycological exam was negative. Histology showed a lymphoplasmacytic superficial and deep perivascular, and periadnexal, dermal infiltrate, without epidermal changes. Lesions spontaneously regressed in 4 months. The diagnosis was clinically and histologically consistent with erythema annulare centrifugum, following the exclusion of other differential diagnoses. Erythema annulare centrifugum represents a delayed-type hypersensitivity reaction generally considered idiopathic or otherwise related to numerous triggers, including drugs such as biologics. We describe the first reported case of tocilizumab-induced erythema annulare centrifugum. This case should alert dermatologists to this relatively rare and complex entity and should raise awareness to cutaneous biologic drug reactions.
- 13 October 2022
- Published by S. Karger AG in Case Reports in Dermatology
- Vol. 14 (3) , 302-306
Open AccessTocilizumab-Induced Erythema Annulare Centrifugum
We report the case of a 42-year-old woman with rheumatoid arthritis undergoing treatment with subcutaneous tocilizumab for the past 6 months. Three days after the administration, an asymptomatic inflammatory annular plaque of 4 cm with discrete whitish scales at the inner border margin developed at the injection site in the left iliac fossa. A smaller plaque in the left groin appeared soon after. The mycological exam was negative. Histology showed a lymphoplasmacytic superficial and deep perivascular, and periadnexal, dermal infiltrate, without epidermal changes. Lesions spontaneously regressed in 4 months. The diagnosis was clinically and histologically consistent with erythema annulare centrifugum, following the exclusion of other differential diagnoses. Erythema annulare centrifugum represents a delayed-type hypersensitivity reaction generally considered idiopathic or otherwise related to numerous triggers, including drugs such as biologics. We describe the first reported case of tocilizumab-induced erythema annulare centrifugum. This case should alert dermatologists to this relatively rare and complex entity and should raise awareness to cutaneous biologic drug reactions.
- Open Access
- 19 January 2022
- Published by S. Karger AG in Skin Appendage Disorders
- Vol. 8 (4) , 280-286
Dermatitis Cruris Pustulosa et Atrophicans: Scarring Alopecia Beyond Scalp Hair
Dermatitis Cruris Pustulosa et Atrophicans (DCPA) was first described in 1952 in Nigeria and is nowadays regarded as a type of chronic folliculitis of tropical areas. It is often limited to the lower limbs of young adults, mostly in the second to third decades, with a unique clinical picture characterized by chronicity, relentless progression, therapy refractoriness, and permanent cicatricial changes. Trauma, occlusion, and microorganism selection contribute for its etiopathogenesis, which is deemed multifactorial but still incompletely understood. Despite its conspicuous clinical features, awareness of DCPA is apparently low, hence probably overlooked. We herein summarize the current state of knowledge regarding this distinct entity, and further present the first report in a patient from Bangladesh, and concurrently the first in Europe. Paucity of data, and unraveled definite etiology and treatment, highlight the need for further studies.
- 19 January 2022
- Published by S. Karger AG in Skin Appendage Disorders
- Vol. 8 (4) , 280-286
Open AccessDermatitis Cruris Pustulosa et Atrophicans: Scarring Alopecia Beyond Scalp Hair
Dermatitis Cruris Pustulosa et Atrophicans (DCPA) was first described in 1952 in Nigeria and is nowadays regarded as a type of chronic folliculitis of tropical areas. It is often limited to the lower limbs of young adults, mostly in the second to third decades, with a unique clinical picture characterized by chronicity, relentless progression, therapy refractoriness, and permanent cicatricial changes. Trauma, occlusion, and microorganism selection contribute for its etiopathogenesis, which is deemed multifactorial but still incompletely understood. Despite its conspicuous clinical features, awareness of DCPA is apparently low, hence probably overlooked. We herein summarize the current state of knowledge regarding this distinct entity, and further present the first report in a patient from Bangladesh, and concurrently the first in Europe. Paucity of data, and unraveled definite etiology and treatment, highlight the need for further studies.
- Open Access
- 4 August 2021
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 35 (12) , E839-E841
Retiform purpura and extensive skin necrosis as the single manifestation of SARS‐CoV‐2 infection
- 4 August 2021
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 35 (12) , E839-E841
Open AccessRetiform purpura and extensive skin necrosis as the single manifestation of SARS‐CoV‐2 infection
- 22 March 2021
- Published by S. Karger AG in Skin Appendage Disorders
- Vol. 7 (4) , 318-321
Intermammary Hidradenitis Suppurativa: Considerations on a Unique Presentation
Introduction: Hidradenitis suppurativa (HS) is a potentially disabling chronic inflammatory disease. The intermammary location, not clearly specified in the usual phenotypic classifications, entails significant functional and cosmetic compromise. Case Presentation: Eleven cases of predominantly intermammary disease with multiple fistulization and disfiguring scarring were observed at our Department between January 2016 and March 2020. They were young (mean age = 22 years) obese or overweight women, in which the medical-surgical approach has led to variable results. Discussion/Conclusion: Intermammary HS possibly represents a unique phenotypic presentation, likely to be fistulizing and severe. We believe that anatomo-functional considerations, which can be paralleled to pilonidal sinus disease, contribute to its pathophysiology and striking appearance, and further emphasize the importance of multidisciplinary endeavor to reduce the morbidity associated with this seemingly overlooked location.
- 22 March 2021
- Published by S. Karger AG in Skin Appendage Disorders
- Vol. 7 (4) , 318-321
Intermammary Hidradenitis Suppurativa: Considerations on a Unique Presentation
Introduction: Hidradenitis suppurativa (HS) is a potentially disabling chronic inflammatory disease. The intermammary location, not clearly specified in the usual phenotypic classifications, entails significant functional and cosmetic compromise. Case Presentation: Eleven cases of predominantly intermammary disease with multiple fistulization and disfiguring scarring were observed at our Department between January 2016 and March 2020. They were young (mean age = 22 years) obese or overweight women, in which the medical-surgical approach has led to variable results. Discussion/Conclusion: Intermammary HS possibly represents a unique phenotypic presentation, likely to be fistulizing and severe. We believe that anatomo-functional considerations, which can be paralleled to pilonidal sinus disease, contribute to its pathophysiology and striking appearance, and further emphasize the importance of multidisciplinary endeavor to reduce the morbidity associated with this seemingly overlooked location.